비호지킨림프종 치료제 시장 : 치료법별, 세포 유형별, 약물 유형별, 유통 경로별, 지역별, 경쟁별 예측 및 기회(2020-2030년)
Non-Hodgkin Lymphoma Therapeutics Market By Type of Therapy, By Cell Type, By Drug Type, By Distribution Channel, By Region, Competition Forecast & Opportunities, 2020-2030F
상품코드:1878915
리서치사:TechSci Research
발행일:2025년 11월
페이지 정보:영문 180 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
세계의 비호지킨림프종(NHL) 치료제 시장은 2024년에 81억 9,000만 달러로 평가되었으며, 2030년까지 CAGR 7.61%로 성장하여 127억 2,000만 달러에 달할 것으로 예측됩니다.
비호지킨림프종(NHL) 치료제는 림프계에서 발생하는 다양한 혈액암을 관리하고 치료하기 위해 고안된 일련의 치료법으로 구성되어 있습니다. 화학요법, 표적치료, 면역요법, 방사선치료, 줄기세포 이식 등 다양한 치료법은 악성 세포를 제거하고 환자의 예후를 개선하는 것을 목표로 합니다.
시장 개요
예측 기간
2026-2030년
시장 규모 : 2024년
81억 9,000만 달러
시장 규모 : 2030년
127억 2,000만 달러
CAGR : 2025-2030년
7.61%
가장 빠르게 성장하는 부문
화학요법
최대 시장
북미
주요 시장 촉진요인
면역요법과 CAR T 세포 치료의 발전은 비호지킨림프종 치료제 시장의 주요 시장 촉진요인으로, 매우 효과적이고 전문적인 치료법을 제공하고 있습니다. 이러한 치료법은 환자의 면역체계 또는 유전자 조작된 면역세포를 이용하여 암세포를 정확하게 표적화하여 제거하기 때문에 진행성 또는 난치성 비호지킨림프종에 획기적인 치료 효과를 제공합니다.
주요 시장 과제
첨단 치료법에 따른 높은 비용은 세계 비호지킨림프종(NHL) 치료제 시장의 성장에 큰 장벽으로 작용하고 있습니다. 특히 면역요법을 비롯한 현대적 치료법은 고가의 비용이 드는 경우가 많습니다.
주요 시장 동향
세계 비호지킨림프종 치료제 시장을 주도하는 주요 트렌드는 견조한 파이프라인 개발과 지속적인 신약 출시입니다. 이러한 추세는 기존 카테고리를 넘어 다양한 환자 니즈와 내성 기전에 대응할 수 있는 치료 옵션이 확대되고 있음을 보여줍니다.
목차
제1장 제품 개요
제2장 조사 방법
제3장 주요 요약
제4장 고객의 소리
제5장 세계의 비호지킨림프종(NHL) 치료제 시장 전망
시장 규모 및 예측
금액별
시장 점유율과 예측
치료법별(면역요법, 표적요법, 화학요법, 줄기세포 이식, 기타)
세포 유형별(B세포 림프종, T세포 림프종)
약물 유형별(레블리미드, 리툭산, 키트루다, 임브루비카, 옵디보, 기타)
유통 채널별(병원 약국, 소매 약국, 온라인 약국, 기타)
지역별
기업별(2024년)
시장 맵
제6장 북미의 비호지킨림프종(NHL) 치료제 시장 전망
시장 규모 및 예측
시장 점유율과 예측
북미 : 국가별 분석
미국
캐나다
멕시코
제7장 유럽의 비호지킨림프종(NHL) 치료제 시장 전망
시장 규모 및 예측
시장 점유율과 예측
유럽 : 국가별 분석
독일
프랑스
영국
이탈리아
스페인
제8장 아시아태평양의 비호지킨림프종(NHL) 치료제 시장 전망
시장 규모 및 예측
시장 점유율과 예측
아시아태평양 : 국가별 분석
중국
인도
일본
한국
호주
제9장 중동 및 아프리카의 비호지킨림프종(NHL) 치료제 시장 전망
시장 규모 및 예측
시장 점유율과 예측
중동 및 아프리카 : 국가별 분석
사우디아라비아
아랍에미리트
남아프리카공화국
제10장 남미의 비호지킨림프종(NHL) 치료제 시장 전망
시장 규모 및 예측
시장 점유율과 예측
남미 : 국가별 분석
브라질
콜롬비아
아르헨티나
제11장 시장 역학
성장 촉진요인
과제
제12장 시장 동향과 발전
인수합병
제품 출시
최근 동향
제13장 세계의 비호지킨림프종(NHL) 치료제 시장 : SWOT 분석
제14장 Porter's Five Forces 분석
업계내 경쟁
신규 참여의 가능성
공급업체의 능력
고객의 능력
대체품의 위협
제15장 경쟁 구도
AstraZeneca PLC
Baxter International Inc.
Bayer AG
Novartis AG
Eli Lilly and Company.
Spectrum Pharmaceuticals, Inc.
Teva Pharmaceutical Industries Ltd.
Bristol Myers Squibb Company
GlaxoSmithKline PLC
Janssen Pharmaceuticals, Inc.
제16장 전략적 제안
제17장 조사 회사 소개 및 면책사항
KSM
영문 목차
영문목차
The Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market , valued at USD 8.19 Billion in 2024, is projected to experience a CAGR of 7.61% to reach USD 12.72 Billion by 2030. Non-Hodgkin Lymphoma (NHL) therapeutics comprise a range of medical treatments designed to manage and combat this diverse group of blood cancers originating within the lymphatic system. These therapies, encompassing chemotherapy, targeted therapy, immunotherapy, radiation, and stem cell transplantation, aim to eliminate malignant cells and improve patient outcomes.
Market Overview
Forecast Period
2026-2030
Market Size 2024
USD 8.19 Billion
Market Size 2030
USD 12.72 Billion
CAGR 2025-2030
7.61%
Fastest Growing Segment
Chemotherapy
Largest Market
North America
Key Market Drivers
Advancements in immunotherapy and CAR T-cell therapies are a primary driver for the Non-Hodgkin Lymphoma therapeutics market, introducing highly effective and specialized treatments. These modalities utilize the patient's immune system or engineered immune cells to precisely target and eliminate cancer cells, offering transformative outcomes for aggressive or refractory NHL. Their increasing adoption, including expansion into earlier lines of treatment, significantly boosts market value. According to Gilead Sciences' full year 2024 financial results, released in February 2025, Cell Therapy product sales, encompassing NHL therapies like Yescarta, increased by 6% to reach $2.0 billion in the full year 2024 compared to 2023, reflecting substantial commercial success and clinical integration.
Key Market Challenges
The high cost associated with advanced therapeutic modalities presents a significant impediment to the growth of the Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market. Modern treatments, particularly immunotherapies, often feature substantial price tags. This directly limits patient access to potentially life-saving or life-extending therapies, especially in healthcare systems with stringent budgetary controls or for individuals with inadequate insurance coverage. Even for patients with coverage, significant out-of-pocket expenses can lead to treatment delays or abandonment, compromising optimal patient outcomes.
Key Market Trends
A significant trend driving the Global Non-Hodgkin Lymphoma therapeutics market is the robust pipeline development and continuous launch of novel drugs. This trend signifies a broader expansion of therapeutic options beyond established categories, addressing diverse patient needs and resistance mechanisms. According to OncLive, almost 20 FDA approvals occurred in the hematology sphere in 2024, demonstrating consistent innovation across blood cancers. This influx of new treatments provides clinicians with more tools to manage the complex and varied subtypes of NHL, including those that are aggressive or refractory.
Key Market Players
AstraZeneca PLC
Baxter International Inc.
Bayer AG
Novartis AG
Eli Lilly and Company.
Spectrum Pharmaceuticals, Inc.
Teva Pharmaceutical Industries Ltd.
Bristol Myers Squibb Company
GlaxoSmithKline PLC
Janssen Pharmaceuticals, Inc.
Report Scope:
In this report, the Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Non-Hodgkin Lymphoma (NHL) Therapeutics Market , By Type of Therapy:
Immunotherapy
Targeted Therapy
Chemotherapy
Stem Cell Transplant
Others
Non-Hodgkin Lymphoma (NHL) Therapeutics Market , By Cell Type:
B-cell Lymphomas
T-cell Lymphomas
Non-Hodgkin Lymphoma (NHL) Therapeutics Market , By Drug Type:
Revlimid
Rituxan
Keytruda
Imbruvica
Opdivo
Others
Non-Hodgkin Lymphoma (NHL) Therapeutics Market , By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others
Non-Hodgkin Lymphoma (NHL) Therapeutics Market , By Region:
North America
United States
Canada
Mexico
Europe
France
United Kingdom
Italy
Germany
Spain
Asia Pacific
China
India
Japan
Australia
South Korea
South America
Brazil
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies presents in the Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market .
Available Customizations:
Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Type of Therapy (Immunotherapy, Targeted Therapy, Chemotherapy, Stem Cell Transplant, Others)
5.2.2. By Cell Type (B-cell Lymphomas, T-cell Lymphomas)
5.2.3. By Drug Type (Revlimid, Rituxan, Keytruda, Imbruvica, Opdivo, Others)
5.2.4. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others)
5.2.5. By Region
5.2.6. By Company (2024)
5.3. Market Map
6. North America Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Type of Therapy
6.2.2. By Cell Type
6.2.3. By Drug Type
6.2.4. By Distribution Channel
6.2.5. By Country
6.3. North America: Country Analysis
6.3.1. United States Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Type of Therapy
6.3.1.2.2. By Cell Type
6.3.1.2.3. By Drug Type
6.3.1.2.4. By Distribution Channel
6.3.2. Canada Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Type of Therapy
6.3.2.2.2. By Cell Type
6.3.2.2.3. By Drug Type
6.3.2.2.4. By Distribution Channel
6.3.3. Mexico Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Type of Therapy
6.3.3.2.2. By Cell Type
6.3.3.2.3. By Drug Type
6.3.3.2.4. By Distribution Channel
7. Europe Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Type of Therapy
7.2.2. By Cell Type
7.2.3. By Drug Type
7.2.4. By Distribution Channel
7.2.5. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Type of Therapy
7.3.1.2.2. By Cell Type
7.3.1.2.3. By Drug Type
7.3.1.2.4. By Distribution Channel
7.3.2. France Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Type of Therapy
7.3.2.2.2. By Cell Type
7.3.2.2.3. By Drug Type
7.3.2.2.4. By Distribution Channel
7.3.3. United Kingdom Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Type of Therapy
7.3.3.2.2. By Cell Type
7.3.3.2.3. By Drug Type
7.3.3.2.4. By Distribution Channel
7.3.4. Italy Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Type of Therapy
7.3.4.2.2. By Cell Type
7.3.4.2.3. By Drug Type
7.3.4.2.4. By Distribution Channel
7.3.5. Spain Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Type of Therapy
7.3.5.2.2. By Cell Type
7.3.5.2.3. By Drug Type
7.3.5.2.4. By Distribution Channel
8. Asia Pacific Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Type of Therapy
8.2.2. By Cell Type
8.2.3. By Drug Type
8.2.4. By Distribution Channel
8.2.5. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Type of Therapy
8.3.1.2.2. By Cell Type
8.3.1.2.3. By Drug Type
8.3.1.2.4. By Distribution Channel
8.3.2. India Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Type of Therapy
8.3.2.2.2. By Cell Type
8.3.2.2.3. By Drug Type
8.3.2.2.4. By Distribution Channel
8.3.3. Japan Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Type of Therapy
8.3.3.2.2. By Cell Type
8.3.3.2.3. By Drug Type
8.3.3.2.4. By Distribution Channel
8.3.4. South Korea Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Type of Therapy
8.3.4.2.2. By Cell Type
8.3.4.2.3. By Drug Type
8.3.4.2.4. By Distribution Channel
8.3.5. Australia Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Type of Therapy
8.3.5.2.2. By Cell Type
8.3.5.2.3. By Drug Type
8.3.5.2.4. By Distribution Channel
9. Middle East & Africa Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Type of Therapy
9.2.2. By Cell Type
9.2.3. By Drug Type
9.2.4. By Distribution Channel
9.2.5. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Type of Therapy
9.3.1.2.2. By Cell Type
9.3.1.2.3. By Drug Type
9.3.1.2.4. By Distribution Channel
9.3.2. UAE Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Type of Therapy
9.3.2.2.2. By Cell Type
9.3.2.2.3. By Drug Type
9.3.2.2.4. By Distribution Channel
9.3.3. South Africa Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Type of Therapy
9.3.3.2.2. By Cell Type
9.3.3.2.3. By Drug Type
9.3.3.2.4. By Distribution Channel
10. South America Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Type of Therapy
10.2.2. By Cell Type
10.2.3. By Drug Type
10.2.4. By Distribution Channel
10.2.5. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Type of Therapy
10.3.1.2.2. By Cell Type
10.3.1.2.3. By Drug Type
10.3.1.2.4. By Distribution Channel
10.3.2. Colombia Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Type of Therapy
10.3.2.2.2. By Cell Type
10.3.2.2.3. By Drug Type
10.3.2.2.4. By Distribution Channel
10.3.3. Argentina Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Type of Therapy
10.3.3.2.2. By Cell Type
10.3.3.2.3. By Drug Type
10.3.3.2.4. By Distribution Channel
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market : SWOT Analysis
